NSABP B-43

Closed to Accrual

Return to Protocol Table

A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

Principal Investigator

Melody Cobleigh, MD

Status

Closed to Accrual

Date Opened To Accrual

November 10 2008

Date Closed to Accrual

December 08 2014

Disease Site

Breast [BR]

Breast

Phase

III

Developmental Therapeutics

Primary Objective

To determine the value of trastuzumab given during radiation therapy (RT) compared to RT alone in preventing the subsequent occurrence of ipsilateral breast cancer recurrence, ipsilateral skin cancer recurrence, or ipsilateral DCIS
(IIBCR-SCR-DCIS) in women with HER2-positive DCIS resected by lumpectomy.

Patient Population

Women with HER2-positive ductal carcinoma in situ (DCIS) resected by lumpectomy

Target Accrual

2000

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Forms

Study Memos

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.